老年癌症患者的药物相互作用：来自国际老年肿瘤学会第15届会议的报告，2015年11月于捷克共和国布拉格
Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015.
作者信息
Stepney Rob, Lichtman Stuart M, Danesi Romano
机构信息
2 Walcot Farm Cottages, Charlbury, Oxfordshire, OX7 3HJ, UK.
Memorial Sloan Kettering Cancer Center, Commack, NY, USA.
出版信息
Ecancermedicalscience. 2016 Jan 14;10:611. doi: 10.3332/ecancer.2016.611. eCollection 2016.
Abstract
Drugs taken for cancer can interact with each other, with agents taken as part of supportive care, with drugs taken for comorbid conditions (which are particularly common in the elderly patients), and with herbal supplements and complementary medicines. We tend to focus on the narrow therapeutic window of cytotoxics, but the metabolism of tyrosine kinase inhibitors by the cytochrome P450 3A4 enzyme (CYP3A4) makes some TKIs particularly prone to interference with or from other agents sharing this pathway. There is also potential for adverse pharmacokinetic interactions with new hormonal agents used in advanced prostate cancer.
摘要
用于治疗癌症的药物可能会相互作用，也会与作为支持性治疗一部分使用的药物、用于治疗合并症（在老年患者中尤为常见）的药物以及草药补充剂和辅助药物发生相互作用。我们往往将重点放在细胞毒性药物狭窄的治疗窗上，但细胞色素P450 3A4酶（CYP3A4）对酪氨酸激酶抑制剂的代谢使得一些酪氨酸激酶抑制剂特别容易受到共享该途径的其他药物的干扰或对其产生干扰。晚期前列腺癌中使用的新型激素药物也存在不良药代动力学相互作用的可能性。
相似文献
1
Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015.老年癌症患者的药物相互作用：来自国际老年肿瘤学会第15届会议的报告，2015年11月于捷克共和国布拉格
Ecancermedicalscience. 2016 Jan 14;10:611. doi: 10.3332/ecancer.2016.611. eCollection 2016.
2
Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.酪氨酸激酶抑制剂的药代动力学药物相互作用：聚焦于细胞色素P450、转运体及抑酸治疗。
Hematol Oncol. 2017 Sep;35(3):259-280. doi: 10.1002/hon.2335. Epub 2016 Dec 7.
3
Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).细胞色素P450酶介导的草药药物相互作用（第1部分）。
EXCLI J. 2014 Apr 2;13:347-91. eCollection 2014.
4
5
The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.澳大利亚社区居住老年人中临床相关CYP酶抑制剂与底物药物联合处方的流行情况。
J Clin Pharm Ther. 2014 Aug;39(4):383-9. doi: 10.1111/jcpt.12163. Epub 2014 Apr 7.
6
Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients.涉及住院老年患者中 CYP3A4 和 P-糖蛋白的药物-药物相互作用。
Eur J Intern Med. 2019 Jul;65:51-57. doi: 10.1016/j.ejim.2019.05.002. Epub 2019 May 10.
7
Effect of Chinese herbs on CYP3A4 activity and expression in vitro.中药对 CYP3A4 体外活性和表达的影响。
J Ethnopharmacol. 2013 Sep 16;149(2):543-9. doi: 10.1016/j.jep.2013.07.014. Epub 2013 Jul 20.
8
Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.临床上重要的药物相互作用可能涉及基于机制的细胞色素P450 3A4抑制作用以及治疗药物监测的作用。
Ther Drug Monit. 2007 Dec;29(6):687-710. doi: 10.1097/FTD.0b013e31815c16f5.
9
Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.预测癌症患者中 CYP3A4 介导的草药-药物相互作用的体外和临床数据的相关性。
Cancer Treat Rev. 2013 Nov;39(7):773-83. doi: 10.1016/j.ctrv.2012.12.008. Epub 2013 Feb 8.
10
Clinically significant drug interactions with antidepressants in the elderly.老年人中与抗抑郁药具有临床意义的药物相互作用。
Drugs Aging. 2002;19(4):299-320. doi: 10.2165/00002512-200219040-00004.
引用本文的文献
1
Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN System Comprehensive Approach.结直肠癌患者的药物相互作用与药物基因组学评估：新型Drug-PIN系统综合方法
Pharmaceuticals (Basel). 2021 Jan 15;14(1):67. doi: 10.3390/ph14010067.
2
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.评估非转移性去势抵抗性前列腺癌患者达罗他胺的临床相关药物-药物相互作用和群体药代动力学：III 期ARAMIS 试验的预设和事后分析结果。
Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.
3
Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer.用于治疗非小细胞肺癌的表皮生长因子受体酪氨酸激酶抑制剂的药物相互作用比较综述
Onco Targets Ther. 2019 Jul 9;12:5467-5484. doi: 10.2147/OTT.S194870. eCollection 2019.
4
Identifying Drug Interactions between Enzalutamide and Complementary Alternative Medications in a Patient with Metastatic Prostate Cancer: A Case Report.转移性前列腺癌患者中恩杂鲁胺与补充替代药物之间的药物相互作用识别：一例报告
Can J Hosp Pharm. 2018 Jul-Aug;71(4):276-281. Epub 2018 Aug 28.
5
Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers.肿瘤医生、老年患者及其照护者之间基于老年综合评估的药物治疗讨论。
J Geriatr Oncol. 2018 Sep;9(5):534-539. doi: 10.1016/j.jgo.2018.02.007. Epub 2018 Mar 9.
本文引用的文献
1
Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.醋酸阿比特龙治疗转移性去势抵抗性前列腺癌的药代动力学、药效学及临床疗效
Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):967-75. doi: 10.1517/17425255.2015.1041918. Epub 2015 May 4.
2
Clinical Pharmacokinetic Studies of Enzalutamide.恩杂鲁胺的临床药代动力学研究。
Clin Pharmacokinet. 2015 Oct;54(10):1043-55. doi: 10.1007/s40262-015-0271-5.
3
The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010.多重用药及药物相互作用的上升趋势：1995 - 2010年人群数据库分析
BMC Med. 2015 Apr 7;13:74. doi: 10.1186/s12916-015-0322-7.
4
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.口服表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌：比较药代动力学和药物相互作用。
Cancer Treat Rev. 2014 Sep;40(8):917-26. doi: 10.1016/j.ctrv.2014.06.010. Epub 2014 Jul 1.
5
Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.老年癌症患者接受化疗时的潜在药物相互作用和化学毒性。
J Geriatr Oncol. 2014 Jul;5(3):307-14. doi: 10.1016/j.jgo.2014.04.002. Epub 2014 May 10.
6
Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs.口服抗肿瘤药物治疗的癌症患者中潜在药物-药物相互作用的流行率。
Br J Cancer. 2013 Mar 19;108(5):1071-8. doi: 10.1038/bjc.2013.48. Epub 2013 Feb 14.
7
Drug interactions in oncology: how common are they?肿瘤学中的药物相互作用：它们有多常见？
Ann Oncol. 2009 Dec;20(12):1907-12. doi: 10.1093/annonc/mdp369. Epub 2009 Aug 27.
8
Drug interactions in cancer therapy.癌症治疗中的药物相互作用。
Nat Rev Cancer. 2006 Jul;6(7):546-58. doi: 10.1038/nrc1887.
Zotero 插件